LNTH Overview
Upcoming Projects (LNTH)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (LNTH)
-
A Third Look: Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LNTH, LLY, FUSN
Executed On: Mar 12, 2024 at 01:00 PM EDT -
A Second Look: Discussing the current radiopharmaceutical landscape for prostate cancer and different approaches to radioligand therapies in development.
Tickers: LNTH, NVS, LLY, FUSN
Executed On: Feb 02, 2024 at 09:00 AM EST -
A Second Look: Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LNTH, LLY, FUSN
Executed On: Feb 01, 2024 at 04:30 PM EST -
Discussing the current treatment landscape for radiopharmaceuticals, therapies in development, and Pluvicto’s PSMAfore data presented in November at ESMO.
Tickers: NVS, LLY, LNTH, FUSN
Executed On: Jan 26, 2024 at 08:00 AM EST -
Discussing the current radiopharmaceutical landscape for prostate cancer and different approaches to radioligand therapies in development.
Tickers: LNTH, NVS, LLY, FUSN
Executed On: Jan 24, 2024 at 12:30 PM EST -
A Fourth View: Discussing Pylarify (piflufolastat F 18) and its relevance as a diagnostic tool for the identification and management of patients with suspected metastasis or recurrent prostate cancer
Ticker: LNTH
Executed On: Mar 25, 2022 at 12:00 PM EDT -
A Third View: Discussing Pylarify (piflufolastat F 18) and its relevance as a diagnostic tool for the identification and management of patients with suspected metastasis or recurrent prostate cancer
Ticker: LNTH
Executed On: Mar 23, 2022 at 01:30 PM EDT -
A 2nd View: Discussing Pylarify (Piflufolastat F 18) and its relevance as a diagnostic for the Prostate cancer treatment paradigm
Ticker: LNTH
Executed On: Mar 21, 2022 at 03:00 PM EDT -
Discussing Pylarify (piflufolastat F 18) and its relevance as a diagnostic tool for the identification and management of patients with suspected metastasis or recurrent prostate cancer
Ticker: LNTH
Executed On: Mar 13, 2022 at 11:45 PM EDT
Upcoming & Overdue Catalysts (LNTH)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (LNTH)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
